# KANDLELIT-001 (NCT05067283)

> A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05067283
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Advanced Solid Tumors
- Interventions: Calderasib; Pembrolizumab; carboplatin; pemetrexed; cetuximab; oxaliplatin; leucovorin; 5-fluorouracil
- Enrollment: 830
- Primary outcome: Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)
- Primary outcome: Number of Participants Who Experience an Adverse Event (AE)
- Primary outcome: Number of Participants Who Discontinue Study Treatment Due to an AE

## Commentary we found

- X threads: 11
- YouTube: 5

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=kandlelit-001-nct05067283

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05067283", "email": "<work email>"}; the inbox owner confirms by the emailed link.